Skip to content

Kenneth Blum

10 papers in the library · 95 citations · publishing 1977-2026

Papers

Sort Most recent Most cited

Adolescent Δ9-THC Exposure Differentially Affects Mice Depending on Their Personality.

Pharmaceuticals June 29, 2026 Dilorom Begmatova, Liudmila Vinnikova, Natalya Zemliana et al.

Background: Adolescence is a sensitive period for brain maturation during which exposure to Δ9-tetrahydrocannabinol (THC) can induce long-lasting neurobehavioral alterations. Yet, preclinical and clinical studies report inconsistent long-term outcomes of adolescent THC exposure, ranging from clear impairments to apparently normalizing effects. We hypothesize that these discrepancies reflect...

The Emerging Crisis in Non-Prescribed Ketamine Use: A Rapid Attenuation of Depression in Face of Abuse and "Chill-out" or Escapism Drug.

Substance Use & Misuse February 1, 2026 Kai-Uwe Lewandrowski, Kenneth Blum, Sergio Schmidt et al.

Since 2000, rates of suicide and opioid overdose have sharply increased. Approximately one-third of individuals with major depressive disorder (MDD) experience treatment-resistant depression (TRD), highlighting the urgent need for novel therapeutic approaches. This review synthesizes pivotal preclinical and clinical findings on low-dose ketamine's rapid antidepressant effects and examines...

Can Psychedelics help with Alcohol Use Disorder (AUD): For now, the data says no.

Science academique 2026 Kenneth Blum, Kai-Uwe Lewandrowski, Morgan P Lorio et al.

The aim of this perspective article is to evaluate the potential of Psychedelics in the management of Alcohol Use Disorder (AUD) vis-a-vis pre-existing therapeutic modalities and to elucidate practical directions for policy in AUD Addiction medicine, supported by scientific evidence, while prioritizing safety and accessibility. We performed a narrative synthesis of past and current literature...

Ketamine's Role in Neuroinflammation and Neuroprotection Across Neurological and Psychiatric Disorders: A Narrative Review.

Pharmaceuticals August 29, 2025 Gustavo N Silva, Virna G A Brandão, Kenneth Blum et al. 7 citations

Ketamine, a widely used anesthetic with emerging evidence suggesting neuroprotective and anti-inflammatory properties across various neurological disorders, is recognized for its NMDA receptor antagonism. It has been postulated to play a role in neuroprotection, due to its anti-inflammatory properties, and decrease microglial activation, as well as cytokines TNF and IL-6. Despite its...

DOI: 10.3390/ph18091298 (opens in new tab) Full text (opens in new tab) Nmda receptors Brain injury Ketamine ketamine Neuroprotection neuroprotection +4

Opioid use disorder: current trends and potential treatments

Frontiers in Public Health January 25, 2024 Yu Kyung Lee, Mark S. Gold, Kenneth Blum et al. 45 citations

Opioid use disorder (OUD) is a major public health threat, contributing to morbidity and mortality from addiction, overdose, and related medical conditions. Despite our increasing knowledge about the pathophysiology and existing medical treatments of OUD, it has remained a relapsing and remitting disorder for decades, with rising deaths from overdoses, rather than declining. The COVID-19...

DOI: 10.3389/fpubh.2023.1274719 (opens in new tab) Hallucinogens Homeostasis Neuroimmunomodulation Opioid-related disorders +3

Vaporized Delta-9-tetrahydrocannabinol Inhalation in Female Sprague Dawley Rats: A Pharmacokinetic and Behavioral Assessment.

Current Pharmaceutical Design 2023 Samantha L Penman, Erin C. Berthold, Abrianna Mihalkovic et al.

Delta-9-tetrahydrocannabinol (THC) is the main psychoactive component of cannabis. Historically, rodent studies examining the effects of THC have used intraperitoneal injection as the route of administration, heavily focusing on male subjects. However, human cannabis use is often through inhalation rather than injection. We sought to characterize the pharmacokinetic and phenotypic profile of...

DOI: 10.2174/1381612829666230419093809 (opens in new tab) Full text (opens in new tab) Cannabis Delta-9-Tetrahydrocannabinol THC Liquid-chromatography/mass-spectrometry Locomotor activity. +2

Epigenetic Repair of Terrifying Lucid Dreams by Enhanced Brain Reward Functional Connectivity and Induction of Dopaminergic Homeostatic Signaling.

Current Psychopharmacology February 15, 2021 Kenneth Blum, Thomas Mclaughlin, Edward J Modestino et al. 9 citations

During Lucid Dreams, the dreamer is aware, experiences the dream as if fully awake, and may control the dream content. The dreamer can start, stop, and restart dreaming, depending on the nature and pleasantness of the dream. For patients with Reward Deficiency Syndrome (RDS) behaviors, like Attention Deficit Hyperactivity Disorder (ADHD), Tourette's- Syndrome, and Posttraumatic Stress Disorder...

DOI: 10.2174/2211556010666210215153513 (opens in new tab) Full text (opens in new tab) Neuroplasticity Lucid dreams Dopaminergic homeostatic signaling Functional connectivity +1

KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit?

Journal of reward deficiency syndrome and addiction science 2016 Thomas Mclaughlin, Marcelo Febo, Rajendra D Badgaiyan et al.

Recent reports by our laboratory have indicated that lucid dreams may be linked to psychiatric conditions, including Attention Deficit Hyperactivity Disorder (ADHD) and other Reward Deficiency Syndrome-related diagnoses. In the latter case, it has been our observation that such lucid dreams can be unpleasant and frequently terrifying. We present four cases of a dramatic and persistent...

Putative dopamine agonist (KB220Z) attenuates lucid nightmares in PTSD patients: role of enhanced brain reward functional connectivity and homeostasis redeeming joy.

Journal of Behavioral Addictions June 1, 2015 Thomas Mclaughlin, Kenneth Blum, Marlene Oscar-Berman et al.

Background: Lucid dreams are frequently pleasant and training techniques have been developed to teach dreamers to induce them. In addition, the induction of lucid dreams has also been used as a way to ameliorate nightmares. On the other hand, lucid dreams may be associated with psychiatric conditions, including Post-Traumatic Stress Disorder (PTSD) and Reward Deficiency Syndrome-associated...

DOI: 10.1556/2006.4.2015.008 (opens in new tab) Full text (opens in new tab) Humans Catecholamines Neprilysin Monoamine oxidase +15

Peyote, a Potential Ethnopharmacologic Agent for Alcoholism and Other Drug Dependencies: Possible Biochemical Rationale

Clinical Toxicology 1977 Kenneth Blum, San Ford L. Futterman, Paul Pascarosa 34 citations

The authors examine folk psychiatry among Native American Church members from an enthnopharmacologic viewpoint. Alcohol and opiate abuse among Indian and non-Indian are presented in case histories proving to be asymptomatic under Indian guidance and through participation in the peyote ritual. The biochemical alkaloids common in the peyote cactus, rather than just the psychoactive substances...

DOI: 10.3109/15563657708988210 (opens in new tab) Mescaline Opiate Hallucinogen Psychoactive substance +4